Paul B.  Manning net worth and biography

Paul Manning Biography and Net Worth

Mr. Manning has served as the Chairman of the Verrica Pharmaceuticals Board of Directors since December 2017, and as a member since December 2015. He is the Chairman and CEO of PBM Capital Group, LLC, a private-equity investment firm he founded in 2010, focused on the healthcare- and life-science-related companies. Prior to that, Mr. Manning founded PBM Products in 1997, a producer of infant formula and baby food, which he sold to Perrigo Corporation in 2010. He was previously a Director of Dova Pharmaceuticals, Inc., a publicly traded pharmaceutical company that was purchased by Sobi, as well as various private companies, and has served on the Boards of Directors at Perrigo Corporation, Concordia Healthcare Corporation and AveXis, Inc. Mr. Manning received his BS in Microbiology from the University of Massachusetts.

What is Paul B. Manning's net worth?

The estimated net worth of Paul B. Manning is at least $98.07 million as of November 17th, 2023. Mr. Manning owns 16,566,667 shares of Verrica Pharmaceuticals stock worth more than $98,074,669 as of March 28th. This net worth approximation does not reflect any other investments that Mr. Manning may own. Learn More about Paul B. Manning's net worth.

How do I contact Paul B. Manning?

The corporate mailing address for Mr. Manning and other Verrica Pharmaceuticals executives is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. Verrica Pharmaceuticals can also be reached via phone at (434) 453-3300 and via email at [email protected]. Learn More on Paul B. Manning's contact information.

Has Paul B. Manning been buying or selling shares of Verrica Pharmaceuticals?

Paul B. Manning has not been actively trading shares of Verrica Pharmaceuticals within the last three months. Most recently, on Monday, July 24th, Paul B. Manning bought 200,000 shares of Verrica Pharmaceuticals stock. The stock was acquired at an average cost of $5.02 per share, with a total value of $1,004,000.00. Following the completion of the transaction, the director now directly owns 7,851,128 shares of the company's stock, valued at $39,412,662.56. Learn More on Paul B. Manning's trading history.

Who are Verrica Pharmaceuticals' active insiders?

Verrica Pharmaceuticals' insider roster includes Matt Davidson (Major Shareholder), A. Davis (CFO), Christopher Hayes (Insider), Paul Manning (Director), and Ted White (CEO). Learn More on Verrica Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Verrica Pharmaceuticals?

During the last year, Verrica Pharmaceuticals insiders bought shares 6 times. They purchased a total of 1,537,691 shares worth more than $8,942,546.19. During the last year, insiders at the sold shares 3 times. They sold a total of 106,046 shares worth more than $471,200.18. The most recent insider tranaction occured on December, 28th when Major Shareholder Perceptive Advisors Llc bought 126,116 shares worth more than $892,901.28. Insiders at Verrica Pharmaceuticals own 41.5% of the company. Learn More about insider trades at Verrica Pharmaceuticals.

Information on this page was last updated on 12/28/2023.

Paul B. Manning Insider Trading History at Verrica Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/24/2023Buy200,000$5.02$1,004,000.007,851,128View SEC Filing Icon  
12/2/2021Buy30,023$9.45$283,717.35View SEC Filing Icon  
3/25/2021Buy739,830$14.75$10,912,492.50View SEC Filing Icon  
8/20/2020Buy20,000$9.09$181,800.00View SEC Filing Icon  
8/17/2020Buy6,000$6.92$41,520.00View SEC Filing Icon  
8/13/2020Buy108,500$6.41$695,485.00View SEC Filing Icon  
10/10/2019Buy20,886$15.08$314,960.88
11/13/2018Buy70,200$14.15$993,330.00View SEC Filing Icon  
8/10/2018Buy33,000$15.08$497,640.00View SEC Filing Icon  
6/19/2018Buy300,000$15.00$4,500,000.00View SEC Filing Icon  
See Full Table

Paul B. Manning Buying and Selling Activity at Verrica Pharmaceuticals

This chart shows Paul B Manning's buying and selling at Verrica Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verrica Pharmaceuticals Company Overview

Verrica Pharmaceuticals logo
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Read More

Today's Range

Now: $5.92
Low: $5.60
High: $6.01

50 Day Range

MA: $5.35
Low: $4.74
High: $5.99

2 Week Range

Now: $5.92
Low: $2.86
High: $7.76

Volume

88,474 shs

Average Volume

130,442 shs

Market Capitalization

$251.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.87